FR18C1020I2 - Sels pharmaceutiquement acceptables de 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide - Google Patents

Sels pharmaceutiquement acceptables de 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide

Info

Publication number
FR18C1020I2
FR18C1020I2 FR18C1020C FR18C1020C FR18C1020I2 FR 18C1020 I2 FR18C1020 I2 FR 18C1020I2 FR 18C1020 C FR18C1020 C FR 18C1020C FR 18C1020 C FR18C1020 C FR 18C1020C FR 18C1020 I2 FR18C1020 I2 FR 18C1020I2
Authority
FR
France
Prior art keywords
indazole
piperidin
carboxamide
phenyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR18C1020C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40404013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR18C1020(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of FR18C1020I1 publication Critical patent/FR18C1020I1/fr
Application granted granted Critical
Publication of FR18C1020I2 publication Critical patent/FR18C1020I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
FR18C1020C 2008-01-08 2018-05-14 Sels pharmaceutiquement acceptables de 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide Active FR18C1020I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1033308P 2008-01-08 2008-01-08
PCT/GB2009/000041 WO2009087381A1 (en) 2008-01-08 2009-01-08 Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide

Publications (2)

Publication Number Publication Date
FR18C1020I1 FR18C1020I1 (https=) 2018-07-13
FR18C1020I2 true FR18C1020I2 (fr) 2019-06-07

Family

ID=40404013

Family Applications (1)

Application Number Title Priority Date Filing Date
FR18C1020C Active FR18C1020I2 (fr) 2008-01-08 2018-05-14 Sels pharmaceutiquement acceptables de 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide

Country Status (16)

Country Link
US (1) US8436185B2 (https=)
EP (1) EP2240466B1 (https=)
JP (1) JP5989965B2 (https=)
KR (1) KR101653548B1 (https=)
CN (2) CN106008460B (https=)
AU (1) AU2009203598B2 (https=)
BR (1) BRPI0906020A2 (https=)
CA (1) CA2711491C (https=)
ES (1) ES2548131T3 (https=)
FR (1) FR18C1020I2 (https=)
IL (1) IL206201A (https=)
MX (1) MX337421B (https=)
NL (1) NL300938I2 (https=)
NZ (1) NZ586675A (https=)
WO (1) WO2009087381A1 (https=)
ZA (1) ZA201003902B (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2340244A4 (en) 2008-10-14 2012-07-25 Ning Xi COMPOUNDS AND APPLICATION PROCEDURES
ES2578990T3 (es) 2009-03-21 2016-08-03 Sunshine Lake Pharma Co., Ltd. Derivados de amino éster, sales de los mismos y métodos de uso
EP2534153B2 (en) 2010-02-12 2024-05-22 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
LT3157566T (lt) 2014-06-17 2019-08-12 Vertex Pharmaceuticals Incorporated Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
EA201792184A1 (ru) 2015-04-01 2018-04-30 Анаптисбайо, Инк. Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
JP6727660B2 (ja) * 2015-09-30 2020-07-22 国立大学法人東北大学 糖尿病性腎症の判定マーカー
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
KR20230042136A (ko) 2016-06-29 2023-03-27 테사로, 인코포레이티드 난소암의 치료 방법
CN107663190B (zh) * 2016-07-29 2020-06-09 钟桂发 一种尼拉帕尼及其中间体的制备方法以及中间体化合物
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
CN106432057A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法
SG11201903867YA (en) 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
CA3041684C (en) 2016-11-01 2023-09-26 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (pd-1)
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
MX2019008208A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-tim-3.
BR112019020211A2 (pt) * 2017-03-27 2020-04-22 Tesaro, Inc. composições de niraparib
KR20190130625A (ko) * 2017-03-27 2019-11-22 테사로, 인코포레이티드 니라파립 제제
JP7118347B2 (ja) * 2017-04-04 2022-08-16 コンビフォス カタリスツ インコーポレイテッド 重水素化（ｓ）２－（４－（ピペリジン－３－イル）フェニル）－２ｈ－インダゾール－７－カルボキサミド
WO2018191141A1 (en) 2017-04-13 2018-10-18 Janssen Pharmaceutica Nv Combination therapy for prostate cancer
KR102582624B1 (ko) 2017-04-24 2023-09-22 테사로, 인코포레이티드 니라파립의 제조 방법
EP3615572A1 (en) 2017-04-27 2020-03-04 Tesaro Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
AU2018270112A1 (en) * 2017-05-18 2019-12-12 Tesaro, Inc. Combination therapies for treating cancer
CN108530425A (zh) * 2017-05-27 2018-09-14 广州科锐特生物科技有限公司 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法
CN109081828B (zh) * 2017-06-14 2021-03-26 上海时莱生物技术有限公司 聚(adp-核糖)聚合酶抑制剂、制备方法及用途
US10927095B2 (en) 2017-08-14 2021-02-23 Teva Pharmaceuticals International Gmbh Processes for the preparation of Niraparib and intermediates thereof
CN111094981B (zh) * 2017-09-13 2024-04-16 B.R.A.H.M.S有限公司 Pct和pro-adm作为监测抗生素治疗的标记物
US20200271666A1 (en) * 2017-09-13 2020-08-27 B.R.A.H.M.S Gmbh Proadrenomedullin as indicator for renal replacement therapy in critically ill patients
WO2019053116A1 (en) * 2017-09-13 2019-03-21 B.R.A.H.M.S Gmbh FLUID THERAPY GUIDING METHOD BASED ON PROADRENOMEDULLINE
KR20250016494A (ko) * 2017-09-26 2025-02-03 테사로, 인코포레이티드 니라파립 제제
EP3697442A4 (en) 2017-09-30 2021-07-07 Tesaro, Inc. COMBINATION THERAPIES FOR TREATMENT OF CANCER
SG11202002499TA (en) 2017-10-06 2020-04-29 Tesaro Inc Combination therapies and uses thereof
SG11202006147SA (en) 2017-12-27 2020-07-29 Tesaro Inc Methods of treating cancer
AU2019215450A1 (en) 2018-02-05 2020-08-27 Tesaro, Inc Pediatric niraparib formulations and pediatric treatment methods
TWI852940B (zh) 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
WO2020072797A1 (en) * 2018-10-03 2020-04-09 Tesaro, Inc. Niraparib salts
US20210347758A1 (en) * 2018-10-03 2021-11-11 Tesaro, Inc. Crystalline Forms of Niraparib Freebase
WO2020072860A1 (en) * 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Niraparib solid state form
WO2020225753A2 (en) 2019-05-06 2020-11-12 Tesaro, Inc. Methods for characterizing and treating a cancer type using cancer images
CN110407704B (zh) * 2019-08-19 2022-05-17 常州沃腾化工科技有限公司 一种3-甲酰基-2-硝基苯甲酸甲酯的合成方法
UY39201A (es) 2020-05-08 2021-11-30 Janssen Pharmaceutica Nv Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib
US20240325369A1 (en) 2021-07-19 2024-10-03 Janssen Pharmaceutica Nv Treatment of metastatic castration-resistant prostate cancer with niraparib
AU2023214795A1 (en) 2022-02-04 2024-09-19 Janssen Pharmaceutica Nv Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
WO2023159066A1 (en) 2022-02-15 2023-08-24 Tesaro, Inc. Use of niraparib for the treatment of brain cancer
WO2024238587A1 (en) 2023-05-17 2024-11-21 Tesaro, Inc. Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer
CN121443291A (zh) 2023-08-02 2026-01-30 詹森药业有限公司 尼拉帕尼和阿比特龙组合用于治疗转移性去势抵抗性前列腺癌
CN117843713A (zh) * 2023-12-18 2024-04-09 上海亲合力生物医药科技股份有限公司 基于肿瘤微环境激活的激酶抑制剂、组合物及应用
CN119707921B (zh) * 2024-12-19 2026-03-03 四川轻化工大学 一种尼拉帕尼的合成方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
AT401651B (de) * 1994-06-14 1996-11-25 Biochemie Gmbh 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4-
IL123147A (en) 1995-08-02 2004-02-19 Univ Newcastle Ventures Ltd Benzamide imidazole - 4 carboxamide and their use
JP2002515488A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法
IL142760A (en) 1998-10-30 2005-12-18 Lonza Ag Method for producing 4-Ä(2',5'-diamino-6'- halopyrimidine-4' -yl) aminoÜ-cyclopent -2- enyl-methanols
DE59911249D1 (de) 1998-11-03 2005-01-13 Abbott Gmbh & Co Kg Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
DK1131301T3 (da) 1998-11-17 2006-01-09 Abbott Gmbh & Co Kg 2-phenylbenzimidazoler og 2-phenylindoler, fremstilling af anvendelse heraf
CA2352554C (en) 1998-11-27 2006-10-10 Basf Aktiengesellschaft Substituted benzimidazoles and their use as parp inhibitors
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
WO2001021615A1 (fr) 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
US6508365B1 (en) * 1999-12-28 2003-01-21 Pitney Bowes Inc. Method of removing mail from a mailstream using an incoming mail sorting apparatus
WO2001057038A1 (de) 2000-02-01 2001-08-09 Basf Aktiengesellschaft Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
JPWO2002068407A1 (ja) 2001-02-28 2004-06-24 山之内製薬株式会社 ベンゾイミダゾール化合物
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
JPWO2003062234A1 (ja) 2002-01-23 2005-05-19 山之内製薬株式会社 キノキサリン化合物
US20040034078A1 (en) 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
WO2004014861A1 (ja) 2002-08-09 2004-02-19 Kyorin Pharmaceutical Co., Ltd. 4-置換キノリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
AU2004259741A1 (en) * 2003-07-21 2005-02-03 Smithkline Beecham Corporation (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof
US20050288295A1 (en) * 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
GB0327740D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
WO2005066136A1 (en) 2003-12-22 2005-07-21 Eli Lilly And Company Bicyclic derivatives as ppar modulators
DK1794163T3 (da) 2004-09-22 2010-04-12 Pfizer Fremgangsmåde til fremstilling af poly(ADP-ribose)polymeraseinhibitorer
ATE479687T1 (de) * 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
KR101280096B1 (ko) 2005-06-29 2013-06-28 컴퓨메딕스 리미티드 전도성 브리지를 포함하는 센서 어셈블리
EP1957477B1 (en) 2005-09-29 2011-12-07 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
WO2007059230A2 (en) * 2005-11-15 2007-05-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
EP2007733B1 (en) * 2006-04-03 2016-05-25 MSD Italia S.r.l. Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
CA2647373C (en) * 2006-05-02 2014-03-18 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
US7892667B2 (en) * 2006-09-13 2011-02-22 Altek Corporation Battery security device
AR064777A1 (es) * 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
JP2008228154A (ja) * 2007-03-15 2008-09-25 Fujitsu Ltd 表示装置，および遠隔操作装置

Also Published As

Publication number Publication date
IL206201A0 (en) 2010-12-30
AU2009203598A1 (en) 2009-07-16
US20100286203A1 (en) 2010-11-11
JP5989965B2 (ja) 2016-09-07
AU2009203598B2 (en) 2013-09-26
IL206201A (en) 2014-07-31
EP2240466B1 (en) 2015-07-29
ES2548131T3 (es) 2015-10-14
EP2240466A1 (en) 2010-10-20
CN101932572A (zh) 2010-12-29
KR101653548B1 (ko) 2016-09-02
ZA201003902B (en) 2011-02-23
CA2711491A1 (en) 2009-07-16
WO2009087381A1 (en) 2009-07-16
NZ586675A (en) 2012-04-27
MX2010006593A (es) 2010-12-21
RU2495035C2 (ru) 2013-10-10
RU2010133241A (ru) 2012-02-20
JP2011509252A (ja) 2011-03-24
NL300938I2 (nl) 2019-01-08
BRPI0906020A2 (pt) 2015-06-30
CN106008460B (zh) 2022-08-12
FR18C1020I1 (https=) 2018-07-13
US8436185B2 (en) 2013-05-07
CA2711491C (en) 2016-03-08
CN106008460A (zh) 2016-10-12
MX337421B (es) 2016-03-04
KR20100114021A (ko) 2010-10-22

Similar Documents

Publication Publication Date Title
FR18C1020I2 (fr) Sels pharmaceutiquement acceptables de 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide
FIC20200051I1 (fi) Entrektinibi tai sen tautomeerit tai farmaseuttisesti hyväksyttävät suolat
LU92864I2 (fr) Cobicistat ou un de ses sels pharmaceutiquement acceptables
NL300998I1 (nl) Lusutrombopag of farmaceutisch aanvaardbare zouten of solvaten daarvan
CY2017042I1 (el) Ενωσεις πυρρολοπυριμιδινης ως αναστολεις cdk
RU2465270C3 (ru) Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она
BRPI0817537A2 (pt) 4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona
ITMI20061958A1 (it) Set di blocchi per la costruzione di giochi
NO2016014I2 (no) ceritinib eller farmasøytisk akseptable salter derav
EP2003722A4 (en) STACK CELL
DK2021335T3 (da) Heterocykliske forbindelser som C-FMS-kinasehæmmere
BRPI0715617A2 (pt) Derivados do ácido fenoxifenilacético 4-substituído
PL2026747T3 (pl) Doustne kompozycje zapewniające polepszone usuwanie przebarwień nazębnych
BRPI0921596A2 (pt) Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina
NL301214I2 (nl) Lasmiditan en farmaceutisch aanvaardbare zouten daarvan
CR10879A (es) Cyclized derivatives as eg-5 inhibitors
IL219997A0 (en) 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
SMT201400053B (it) Forme farmaceutiche orali di bendamustina
SMT201300070B (it) Composti eterociclici di fenossimetile
JP2009543766A5 (ja) ｍＰＧＥｓ−１阻害剤としての２−アリールインドール誘導体
DK2049480T3 (da) 2-arylindolderivater som mPGES-1-hæmmere
PL2722046T3 (pl) Postać krystaliczna 1 2-((R)-2-metylopirolidyn-2-ylo)-1H-benzoimidazolo-4-karboksyamidu
DK2246477T3 (da) Spunspæl med dobbelt t-form
IL200959A0 (en) Liquid formulations of salts of 4-[2-(4-methylphenylfanyl)phenyl]piperidine
EP2222662A4 (en) INHIBITORS OF KYNURENINE AMINO TRANSFERASE